Goldman pricing assessment

Quote

Anonymous

Guest
How are payors going to reimbursement if an SRE costs $5000. Why would anyone pay $1000 month more than zometa for 17 months for $17000 when an SRE costs $5000? Someone help me understand value proposition and why we are not charging $300 a month more than Zometa (5,000/17m)? I don't want to waste my time in a docs office trying to explain the math
 












Anonymous said:
How are payors going to reimbursement if an SRE costs $5000. Why would anyone pay $1000 month more than zometa for 17 months for $17000 when an SRE costs $5000? Someone help me understand value proposition and why we are not charging $300 a month more than Zometa (5,000/17m)? I don't want to waste my time in a docs office trying to explain the math
Click to expand...

This is how we justify and pay for the BHBU sales force.
 












The cost of an SRE is closer to $15-20,000. The drug is superior to ZA in solid tumors. Doctors want to give their patients the best care possible and XGeva is that drug.
 






Anonymous said:
The cost of an SRE is closer to $15-20,000. The drug is superior to ZA in solid tumors. Doctors want to give their patients the best care possible and XGeva is that drug.
Click to expand...

Right on... It's a superior drug. But cost of an see is still 5 k. Get ur facts right. At the payer end what matters us the contracting price which is going to be less t
than awp
 






Anonymous said:
The cost of an SRE is closer to $15-20,000. The drug is superior to ZA in solid tumors. Doctors want to give their patients the best care possible and XGeva is that drug.
Click to expand...

If the cost of an SRE is 15,000 then it's not cost-effective to give dmab since it takes 20 months of therapy before seeing a difference. That's over $20,000. Do the math. There's no survival advantage adn the only survival signal shows zometa superiority in MM.

Even though we delay SREs, there's no ultimate benefit. I don't see NICE approving
 






Anonymous said:
If the cost of an SRE is 15,000 then it's not cost-effective to give dmab since it takes 20 months of therapy before seeing a difference. That's over $20,000. Do the math. There's no survival advantage adn the only survival signal shows zometa superiority in MM.

Even though we delay SREs, there's no ultimate benefit. I don't see NICE approving
Click to expand...

No drug provides 100% cost offset against the disease it treats. You obviously are a salesperson and not a health economist.
 
















































Anonymous said:
Goldman is responsible for many of the financial and economic problems in the entire country right now.
Click to expand...

Uh, and who allowed Goldman to do so? Who donated nearly $1,000,000 to our now defunct President? Goldman Who controlled Congress? Democrats. Don't make this a political debate blog, go to Huffington Post for that.

Goldman is going what other investment houses will do once they realize that Amgen is in trouble. Or, since you are a conspiracy theorist, maybe they are trying to drive the stock price down so this Administration can take Amgen over because Amgen is too big to fail. Maybe, just maybe...dialysis is a HUGE part of Medicare/Medicaid, if you own the company responsible for that, you can have the tax payers pay for the drugs. Kevin is probably on this as he said that Obamacare was a good thing...yeah, right. Cost Amgen $500,000,0000! I mean it cost Amgen's employees, higher premium, lower coverage, etc. No matter what, Kevin will make out just okay. He will sail off into the sunset in his new G550.
 






Anonymous said:
Uh, and who allowed Goldman to do so? Who donated nearly $1,000,000 to our now defunct President? Goldman Who controlled Congress? Democrats. Don't make this a political debate blog, go to Huffington Post for that.

Goldman is going what other investment houses will do once they realize that Amgen is in trouble. Or, since you are a conspiracy theorist, maybe they are trying to drive the stock price down so this Administration can take Amgen over because Amgen is too big to fail. Maybe, just maybe...dialysis is a HUGE part of Medicare/Medicaid, if you own the company responsible for that, you can have the tax payers pay for the drugs. Kevin is probably on this as he said that Obamacare was a good thing...yeah, right. Cost Amgen $500,000,0000! I mean it cost Amgen's employees, higher premium, lower coverage, etc. No matter what, Kevin will make out just okay. He will sail off into the sunset in his new G550.
Click to expand...

Sick sick sick. I want to know how does Goldman hit it on the head about shorting amgen.

How?
 






Anonymous said:
Sick sick sick. I want to know how does Goldman hit it on the head about shorting amgen.

How?
Click to expand...

Well, to begin with, their most recent approvals are not bearing any real fruit and are not seen to anytime soon. Second, Epo and others coming off patent are on the horizon. Third, who has confidence in Kevin; guy screws up even the best wet dream. Fourth, they know the company is worth more if it is broken up. Amgen is following the path of "big phama". Manufacturing plants are at 40-60% capacity at best. Ireland acquisition was a pure de-risk play to AML, but does management have brass tacks to shut down AML in the next 3-5 years? ACO within the next 2-3 years? Would divest those to contract manufacturing firms. As for R&D, sites could be consolidated/shut down as well. There is simply too much fat in the company, but for now they have $14,000,000,000+ in the bank so they can afford to be make poor strategy/management decisions. Oh, and fifth, and perhaps the most important. They recycle people more than they recycle paper. How many times can an incompetent person be shuffled around; just look at the recent changes. What is Amgen's involuntary turn over rate, must be less than 1%. People who have been there for their entire career think they are God's gift to humanity, when in reality they are complete dolts. As one friend of mine says, they wear helmets and ride the short bus to work.
 






What does this say about management? They aren't on their toes? Bad choices? Bad luck? Or just generally poor stewardship?

We now have the new Vecitbix problem with the EU not liking what they see. Small loss? Maybe, since the rest of the world likes the drug which, by the way has not performed the sales that had been expected. This was to be another life saver aka, blockbuster? Give it a chance, it has been only five years.

Mention is being made about the thought of a breakup as some think that the sum of the various parts is worth more individually, than just one big sale. This could be an answer for Amgen's rather poor performance over the last many years.

The only share lifesaver I see, is a declared dividend and the retirement of Mr. Sharer.
 












Top Bottom
Back
Quote